717 related articles for article (PubMed ID: 22538745)
1. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
2. "Silent" thyrotropin (TSH) expression in acromegaly and clinically non-functioning pituitary adenomas.
Pawlikowski M; Pisarek H; Jaranowska M; Radek M; Winczyk K; Kunert-Radek J
Endokrynol Pol; 2016; 67(5):515-518. PubMed ID: 27403655
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of prolactin in clinically non-functioning pituitary adenomas.
Winczyk K; Toszek J; Swietoslawski J; Wojtczak E; Pawlikowski M
Folia Histochem Cytobiol; 2020; 58(2):90-95. PubMed ID: 32597492
[TBL] [Abstract][Full Text] [Related]
4. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
5. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
6. Clinically silent somatotroph adenomas are common.
Wade AN; Baccon J; Grady MS; Judy KD; O'Rourke DM; Snyder PJ
Eur J Endocrinol; 2011 Jul; 165(1):39-44. PubMed ID: 21493729
[TBL] [Abstract][Full Text] [Related]
7. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
[TBL] [Abstract][Full Text] [Related]
8. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
9. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
Buurman H; Saeger W
Eur J Endocrinol; 2006 May; 154(5):753-8. PubMed ID: 16645024
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
[TBL] [Abstract][Full Text] [Related]
12. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
[TBL] [Abstract][Full Text] [Related]
13. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone-secreting adenomas: pathology and cell biology.
Lopes MB
Neurosurg Focus; 2010 Oct; 29(4):E2. PubMed ID: 20887127
[TBL] [Abstract][Full Text] [Related]
15. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
16. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
17. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary.
Yamada S; Sano T; Stefaneanu L; Kovacs K; Aiba T; Sawano S; Shishiba Y
J Clin Endocrinol Metab; 1993 Feb; 76(2):352-6. PubMed ID: 8432778
[TBL] [Abstract][Full Text] [Related]
18. Blood serum concentrations of gonadotropins and α-subunit in patients with gonadotropinomas in relation to the immunoreactivity of pituitary adenoma.
Pawlikowski Łódź M; Jaranowska M; Fryczak J; Radek M; Świętosławski J; Kunert-Radek J; Winczyk K
Endokrynol Pol; 2018; 69(5):526-529. PubMed ID: 30074232
[TBL] [Abstract][Full Text] [Related]
19. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
Shimon I; Nass D; Hadani M
Pituitary; 2000 May; 2(4):289-94. PubMed ID: 11081151
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of glycoprotein hormone alpha subunit in somatoprolactinic and pure somatotroph adenomas.
Vantyghem MC; Cortet C; Bauters C; Gevaert MH; Dewailly D; Lefebvre J; Mazzucca M
J Endocrinol Invest; 1998; 21(7):434-40. PubMed ID: 9766257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]